Atossa Therapeutics, Inc. (ATOS) vs Seres Therapeutics, Inc. (MCRB)

Atossa Therapeutics, Inc. and Seres Therapeutics, Inc. are both Biotechnology companies. Atossa Therapeutics, Inc. and Seres Therapeutics, Inc. are of similar size ($26.4M and $25.2M). Atossa Therapeutics, Inc. grew revenue faster over the last twelve months: −93.7% against −98.5%. Atossa Therapeutics, Inc. has the higher net margin (0.00% vs −1,192.9%) and the lower return on invested capital (−3,918.8% vs −277.3%). Across the 16 metrics below, Seres Therapeutics, Inc. leads on 9 and Atossa Therapeutics, Inc. on 7.

Valuation

Metric ATOS MCRB Biotechnology median
P/E n/m n/m 8.50
P/S 646.51 12.68 9.71
P/B 0.97 0.69 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA 0.01 n/m 0.64
EV/Sales (6.95) 58.83 9.21
Earnings yield (150.60%) (98.78%) (33.15%)
Free cash flow yield (138.09%) (214.65%) (25.50%)

Profitability

Metric ATOS MCRB Biotechnology median
Gross margin 0.00% 100.00% 65.16%
Operating margin 0.00% (4,462.77%) 0.00%
Net margin 0.00% (1,192.94%) 0.00%
Free cash flow margin 0.00% (2,721.83%) 0.00%
Return on equity (89.23%) (66.57%) (56.36%)
Return on assets (77.91%) (18.31%) (48.04%)
Return on invested capital (3,918.83%) (277.30%) 0.00%

Growth

Metric ATOS MCRB Biotechnology median
Revenue growth (TTM) (93.66%) (98.51%) 6.02%
EPS growth (last fiscal year) (34.73%) 0.00% 30.26%
Revenue growth, 5-year CAGR — (53.03%) 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric ATOS MCRB Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 5.69 2.11 4.72
Net debt to EBITDA 1.12 0.51 0.96

Dividend

Metric ATOS MCRB Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric ATOS MCRB Biotechnology median
Market cap 26.44m 25.15m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack